The use of dupilumab in severe atopic dermatitis during pregnancy: a case report

27Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Atopic dermatitis is a common chronic skin disease that can occur in pregnancy. Current treatments include topical and systemic glucocorticoids and cyclosporine. Presently, the only biologic approved for atopic dermatitis is dupilumab with limited data available regarding its safety profile in pregnancy. Case presentation: We report a case of severe atopic dermatitis treated safely with dupilumab with no adverse maternal or fetal outcomes and resolution of atopic dermatitis postpartum in the absence of maintenance dupilumab therapy. Conclusion: Here we demonstrate the safe use of dupilumab in pregnancy. Further research is needed to elucidate the role of dupilumab in the management of atopic dermatitis during pregnancy.

Cite

CITATION STYLE

APA

Akhtar, N. H., Khosravi-Hafshejani, T., Akhtar, D., Dhadwal, G., & Kanani, A. (2022). The use of dupilumab in severe atopic dermatitis during pregnancy: a case report. Allergy, Asthma and Clinical Immunology, 18(1). https://doi.org/10.1186/s13223-022-00650-w

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free